<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CIPRO HC- ciprofloxacin hydrochloride and hydrocortisone suspension </strong><br>Alcon Laboratories, Inc.<br></p></div>
<h1>
<span class="Bold">CIPRO® HC OTIC</span><br><span class="Bold">(ciprofloxacin hydrochloride and hydrocortisone otic suspension)</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">CIPRO® HC OTIC (ciprofloxacin hydrochloride and hydrocortisone otic suspension) contains the synthetic broad spectrum antibacterial agent, ciprofloxacin hydrochloride, combined with the anti-inflammatory corticosteroid, hydrocortisone, in a preserved, nonsterile suspension for otic use. Each mL of CIPRO® HC OTIC contains ciprofloxacin hydrochloride (equivalent to 2 mg ciprofloxacin), 10 mg hydrocortisone, and 9 mg benzyl alcohol as a preservative. The inactive ingredients are polyvinyl alcohol, sodium chloride, sodium acetate, glacial acetic acid, phospholipon 90H (modified lecithin), polysorbate, and purified water. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH.</p>
<p>Ciprofloxacin, a fluoroquinolone, is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C<span class="Sub">17</span>H<span class="Sub">18</span>FN<span class="Sub">3</span>O<span class="Sub">3</span>•HCI•H<span class="Sub">2</span>O and its chemical structure is as follows:</p>
<div class="Figure"><img alt="
chemical1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70b19501-34b6-4f95-a8dd-dd3e67d22399&amp;name=chemical1.jpg"></div>
<p>Hydrocortisone, pregn-4-ene-3, 20-dione, 11, 17, 21-trihydroxy-(11β)-, is an anti-inflammatory corticosteroid. Its empirical formula is C<span class="Sub">21</span>H<span class="Sub">30</span>O<span class="Sub">5</span> and its chemical structure is:</p>
<div class="Figure"><img alt="
chemical2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70b19501-34b6-4f95-a8dd-dd3e67d22399&amp;name=chemical2.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First">The plasma concentrations of ciprofloxacin were not measured following three drops of otic suspension administration because the systemic exposure to ciprofloxacin is expected to be below the limit of quantitation of the assay (0.05 μg/mL).</p>
<p>Similarly, the predicted C<span class="Sub">max</span> of hydrocortisone is within the range of endogenous hydrocortisone concentration (0-150 ng/mL), and therefore can not be differentiated from the endogenous cortisol.</p>
<p>Preclinical studies have shown that CIPRO® HC OTIC was not toxic to the guinea pig cochlea when administered intratympanically twice daily for 30 days and was only weakly irritating to rabbit skin upon repeated exposure.</p>
<p>Hydrocortisone has been added to aid in the resolution of the inflammatory response accompanying <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>.</p>
<p><span class="Bold">Microbiology</span></p>
<p>Ciprofloxacin has <span class="Italics">in vitro </span>activity against a wide range of gram-positive and gram-negative microorganisms. The bactericidal action of ciprofloxacin results from interference with the enzyme, DNA gyrase, which is needed for the synthesis of bacterial DNA. Cross-resistance has been observed between ciprofloxacin and other fluoroquinolones.</p>
<p>There is generally no cross-resistance between ciprofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides.</p>
<p>Ciprofloxacin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of acute <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> as described in the <span class="Bold Underline"><a href="#splSectionIndicationsUsage">INDICATIONS AND USAGE</a></span> section:</p>
<p><span class="Bold">Aerobic gram-positive microorganism</span></p>
<p><span class="Italics">Staphylococcus aureus</span></p>
<p><span class="Bold">Aerobic gram-negative microorganisms</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Pseudomonas aeruginosa</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">CIPRO® HC OTIC is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> in adult and pediatric patients, one year and older, due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Staphylococcus aureus</span>, and <span class="Italics">Proteus mirabilis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First">CIPRO® HC OTIC is contraindicated in persons with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocortisone, ciprofloxacin or any member of the quinolone class of antimicrobial agents. This nonsterile product should not be used if the tympanic membrane is perforated. Use of this product is contraindicated in <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the external canal including <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span> and herpes simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First"><span class="Bold">NOT FOR OPHTHALMIC USE. NOT FOR INJECTION.</span></p>
<p>CIPRO® HC OTIC should be discontinued at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may require immediate emergency treatment.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-6.1"></a><p></p>
<h2>
GENERAL:
</h2>
<p class="First">As with other antibiotic preparations, use of this product may result in overgrowth of nonsusceptible organisms, including fungi. If the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not improved after one week of therapy, cultures should be obtained to guide further treatment.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.2"></a><p></p>
<h2>
Information for Patients:
</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, discontinue use immediately and contact your physician.</p>
<p>Do not use in the eyes.</p>
<p>Avoid contaminating the dropper with material from the ear, fingers, or other sources.</p>
<p>Protect from light.</p>
<p>Shake well immediately before using.</p>
<p>Discard unused portion after therapy is completed.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-6.3"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility:
</h2>
<p class="First">Eight <span class="Italics">in vitro </span>mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/Microsome Test (Negative)</p>
<p><span class="Italics">E. coli </span>DNA Repair Assay (Negative)</p>
<p>Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell Forward Mutation Assay (Positive)</p>
<p>Chinese Hamster V79 Cell HGPRT Test (Negative)</p>
<p>Syrian Hamster Embryo Cell Transformation Assay (Negative)</p>
<p><span class="Italics">Saccharomyces cerevisiae </span>Point Mutation Assay (Negative)</p>
<p><span class="Italics">Saccharomyces cerevisiae </span>Mitotic Crossover and Gene Conversion Assay (Negative)</p>
<p>Rat Hepatocyte DNA Repair Assay (Positive)</p>
<p>Thus, 2 of the 8 tests were positive, but results of the following 3 <span class="Italics">in vivo </span>test systems gave negative results:</p>
<p>Rat Hepatocyte DNA Repair Assay</p>
<p>Micronucleus Test (Mice)</p>
<p>Dominant Lethal Test (Mice)</p>
<p>Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species. No long term studies of CIPRO® HC OTIC suspension have been performed to evaluate carcinogenic potential.</p>
<p>Fertility studies performed in rats at oral doses of ciprofloxacin up to 100 mg/kg/day revealed no evidence of impairment. This would be over 1000 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated with CIPRO® HC OTIC twice per day.</p>
<p>Long term studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical hydrocortisone. Mutagenicity studies with hydrocortisone were negative.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-6.4"></a><p></p>
<h2>
Pregnancy: Teratogenic Effects. Pregnancy Category C:
</h2>
<p class="First">Reproduction studies have been performed in rats and mice using oral doses of up to 100 mg/kg and IV doses up to 30 mg/kg and have revealed no evidence of harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofloxacin (30 and 100 mg/kg orally) produced <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> resulting in maternal <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and an increased incidence of abortion, but no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed at either dose. After intravenous administration of doses up to 20 mg/kg, no maternal toxicity was produced in the rabbit, and no embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed.</p>
<p>Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</p>
<p>Animal reproduction studies have not been conducted with CIPRO® HC OTIC. No adequate and well controlled studies have been performed in pregnant women. Caution should be exercised when CIPRO® HC OTIC is used by a pregnant woman.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-6.5"></a><p></p>
<h2>
Nursing Mothers:
</h2>
<p class="First">Ciprofloxacin is excreted in human milk with systemic use. It is not known whether ciprofloxacin is excreted in human milk following topical otic administration. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-7"></a><p></p>
<h1>
Pediatric use:
</h1>
<p class="First">The safety and efficacy of CIPRO® HC OTIC have been established in pediatric patients 2 years and older (131 patients) in adequate and well-controlled clinical trials. Although no data are available on patients less than age 2 years, there are no known safety concerns or differences in the disease process in this population which would preclude use of this product in patients one year and older. See <span class="Bold Underline"><a href="#splSectionDosageAdministration">DOSAGE AND ADMINISTRATION</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-8"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">In Phase 3 clinical trials, a total of 564 patients were treated with CIPRO® HC OTIC. Adverse events with at least remote relationship to treatment included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (1.2%) and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (0.4%). The following treatment-related adverse events were each reported in a single patient: <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-9"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First">SHAKE WELL IMMEDIATELY BEFORE USING.</p>
<p>For children (age 1 year and older) and adults, 3 drops of the suspension should be instilled into the affected ear twice daily for seven days. The suspension should be warmed by holding the bottle in the hand for 1-2 minutes to avoid the <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> which may result from the instillation of a <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> solution into the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 30-60 seconds to facilitate penetration of the drops into the ear. Repeat, if necessary, for the opposite ear. Discard unused portion after therapy is completed.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-10"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">CIPRO® HC OTIC is supplied as a white to off-white opaque suspension in a 10 mL bottle with a dropper dispenser.</p>
<p>NDC 0065-8531-10</p>
<p>Store below 77° F (25° C). Avoid freezing. Protect from light.</p>
<p>U.S. Patent Nos. 5,843,930; 5,965,549.</p>
<p><span class="Bold">Licensed to Alcon, Inc. by Bayer Schering Pharma AG.</span></p>
<p><span class="Bold">CIPRO® is a registered trademark of Bayer AG, licensed to Alcon, Inc. by Bayer AG.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Mfd. by:</p>
<p><span class="Bold">ALCON CUSI, S.A.</span></p>
<p>08320 El Masnou - Barcelona</p>
<p>SPAIN</p>
<p>© 2006, 2009 Alcon, Inc.</p>
<p>6-13-932</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-11"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First">NDC 0065-8531-10</p>
<p>CIPRO® HC</p>
<p>OTIC</p>
<p>(ciprofloxacin 0.2% HCl</p>
<p>and hydrocortisone 1%</p>
<p>otic suspension)</p>
<p>        </p>
<p>NOT FOR</p>
<p>OPHTHALMIC</p>
<p>OR ORAL USE</p>
<p>       </p>
<p>10 mL</p>
<p>       </p>
<p><span class="Bold">Rx</span> Only              <span class="Bold">Alcon<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="
carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70b19501-34b6-4f95-a8dd-dd3e67d22399&amp;name=carton.jpg"></div>
<p></p>
<div class="Figure"><img alt="
label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=70b19501-34b6-4f95-a8dd-dd3e67d22399&amp;name=label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CIPRO 		
					HC</strong><br><span class="contentTableReg">ciprofloxacin hydrochloride and hydrocortisone suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-8531</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">AURICULAR (OTIC)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CIPROFLOXACIN HYDROCHLORIDE</strong> (CIPROFLOXACIN) </td>
<td class="formItem">CIPROFLOXACIN</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LECITHIN, SOYBEAN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-8531-10</td>
<td class="formItem">10 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020805</td>
<td class="formItem">03/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Cusi, S.A.</td>
<td class="formItem"></td>
<td class="formItem">462029349</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f89ae7a5-0aeb-4e66-b406-973eb90c48c3</div>
<div>Set id: 70b19501-34b6-4f95-a8dd-dd3e67d22399</div>
<div>Version: 6</div>
<div>Effective Time: 20110812</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
